Master the MR enterography protocol with a step-by-step framework covering FIESTA/TrueFISP cine sequences, coronal T2 HASTE bowel characterization, precisely timed enteric-phase dynamic contrast, and the scanning, interpretive, and clinical pitfalls that most often undermine accurate Crohn’s disease assessment.

Gastrointestinal MRI ✓ Medically Reviewed ⏱ 37 min read Day 14 of 30 — MRI Protocol Mastery Series

MR Enterography Protocol: The Complete Radiographer & Radiologist Guide

At a Glance

🧲 Sequences Used

Coronal/axial FIESTA/TrueFISP (balanced SSFP)
Coronal T2 HASTE (SSFSE), with and without fat saturation
Cine motility sequence (repeated coronal SSFP over ~20 s)
Multiphase coronal/axial 3D T1 fat-saturated post-contrast (enteric, delayed)
Axial DWI (b=0, 400, 800 s/mm²)

💉 Contrast Protocol

10–15 mL (0.1 mmol/kg) gadolinium-based agent at 3.0 mL/s, followed by a 100 mL saline chaser at 3.0 mL/s. Primary enteric phase acquired at 45–50 seconds post-injection, with a delayed phase at 5–7 minutes.

🎯 Artifact Reduction

Primary artifact: bowel peristalsis motion. Remedy: administer an intravenous antispasmodic (Buscopan 20 mg or glucagon 1 mg) immediately before dynamic imaging to transiently paralyze small bowel motility.

⚠️ Key Pitfalls

Radiographers: omitting or mistiming antispasmodic administration
Radiologists: mistaking under-distended bowel for wall thickening
Referrers: accepting a technically inadequate MRE as a true negative

Table of Contents

Introduction
Small Bowel Anatomy Essentials
MR Tissue Relaxation Values
Scanning Technique — 10 Steps
Contrast Media Protocol
Specific Absorption Rate & Dose Reduction
Top 10 Pathologies
Pitfalls — Radiographers
Pitfalls — Radiologists
Pitfalls — Non-Radiology Physicians
Pitfall Comparison Summary
AI & Automation in Enterography
Further Reading
Reducing Artefacts with Patients and Parameters
Parallel Imaging Protocols and Parameters
Conclusion
References

Introduction

A well-executed MR enterography protocol has become the reference-standard cross-sectional technique for evaluating suspected or established small bowel Crohn’s disease, offering radiation-free assessment of mural inflammation, transmural complications, and disease extent that is repeatable across a patient’s entire lifetime of surveillance imaging. Unlike most MRI protocols, MR enterography’s diagnostic yield depends as much on physiological preparation — adequate oral luminal distention and transient pharmacological suppression of peristalsis — as it does on sequence selection, making it one of the more technically demanding studies in a body MRI service’s repertoire.

Crohn’s disease is a chronic, relapsing inflammatory bowel disease that most commonly affects the terminal ileum, and patients frequently require repeated imaging across decades to guide medical and surgical management. This lifetime imaging burden is precisely why MR enterography has displaced CT enterography as the preferred modality wherever available, particularly in younger patients, those requiring frequent monitoring, and pregnant patients — the absence of ionizing radiation is a genuine, cumulative safety advantage rather than a marginal one.

Clinical Context MR enterography answers three distinct clinical questions in a single study: is there active inflammation (and how severe), is there a fixed fibrotic stricture, and is there a penetrating complication such as fistula or abscess. Each question relies on a different combination of sequences — T2/DWI for inflammation, cine motility for distinguishing fibrotic from inflammatory narrowing, and post-contrast fat-saturated T1 for penetrating disease — which is why the multi-sequence protocol described in this guide cannot be meaningfully abbreviated without losing diagnostic scope.

This guide walks through the complete MR enterography workflow: the small bowel anatomy that dictates sequence and coverage planning, relevant relaxation values, a ten-step scanning technique, the enteric-phase dynamic contrast protocol, SAR-conscious parameter selection, the top ten pathologies the protocol is built to detect, and the distinct pitfalls that affect radiographers at the console, radiologists at the workstation, and referring gastroenterologists acting on the report.

🩺

Reliable Contrast Delivery with SATline

Consistent, kink-resistant tubing supports precise 45–50 second enteric-phase timing across every MR enterography case.

Explore SATline →

Small Bowel Anatomy Essentials

The small bowel extends roughly 6–7 meters from the pylorus to the ileocecal valve and is conventionally divided into the duodenum, jejunum, and ileum — each with distinguishing imaging characteristics that inform both localization of disease and interpretation of normal variants.

Duodenum

The duodenum is largely retroperitoneal and C-shaped around the pancreatic head, extending from the pylorus to the ligament of Treitz. It is relatively fixed in position and less relevant to peristalsis-related motion artifact than the more mobile jejunum and ileum, though it remains important for excluding proximal Crohn’s involvement, which — while uncommon — carries prognostic significance when present.

Jejunum

The jejunum occupies the left upper and central abdomen, characterized by thick, feathery mucosal folds (plicae circulares) that create a distinctive “keyboard” pattern on well-distended coronal sequences. Its thicker wall and prominent folds mean jejunal loops can appear falsely thickened when under-distended — a distinction addressed directly in the interpretation pitfalls section below.

Ileum and terminal ileum

The ileum, occupying the right lower abdomen and pelvis, has thinner, more sparse folds than the jejunum and culminates in the terminal ileum — the single most common site of Crohn’s disease involvement and the segment requiring the most deliberate distention strategy, since it is also the segment most prone to peristaltic under-filling due to its narrower caliber and the adjacent ileocecal valve.

Mesentery and vasa recta

The small bowel mesentery carries the superior mesenteric vessels and their branches — the vasa recta — supplying each bowel segment. Engorgement and increased number of these vessels, radiologically termed the comb sign, is a classic extramural marker of active inflammation and a feature radiologists should specifically search for adjacent to any segment of suspected mural thickening.

Clinical Anatomy Pearl Mesenteric lymph nodes, mesenteric fat stranding (“creeping fat” — fibrofatty proliferation wrapping circumferentially around a chronically diseased segment), and the perirectal/perianal soft tissues should all be included in standard coverage, since penetrating and fistulizing Crohn’s disease frequently extends into these compartments independent of luminal findings.

MR Tissue Relaxation Values

Understanding baseline T1 and T2 relaxation times of normal bowel wall and adjacent structures underpins correct interpretation of mural signal changes that define active inflammation versus chronic fibrosis.

Structure	T1 (ms) @ 1.5T	T1 (ms) @ 3T	T2 (ms) @ 1.5T	T2 (ms) @ 3T
Normal bowel wall (muscularis)	~900–1000	~1150–1250	~40–50	~35–42
Actively inflamed bowel wall	~1100–1300	~1350–1550	~70–90	~60–78
Fibrotic (chronic stricture) wall	~800–950	~1050–1200	<40	<35
Mesenteric fat	~240–260	~360–380	~60–70	~55–65
Enteric luminal fluid (distended)	~2000–2800	~2500–3200	>150	>150
Skeletal muscle (reference)	~870	~1420	~47	~32

This relaxation profile explains why actively inflamed bowel wall is characteristically T2 hyperintense relative to skeletal muscle and demonstrates avid, layered enhancement following contrast, whereas chronic fibrotic strictures show comparatively low T2 signal and slow, progressive rather than early avid enhancement — the imaging basis for distinguishing an actively inflamed stricture (which may respond to medical therapy) from a purely fibrotic one (which typically requires endoscopic or surgical management).

Scanning Technique — 10 Steps

Patient preparation and fasting. Confirm 4-hour fasting status; explain the oral contrast ingestion process and the transient bloating/urgency it can produce.
Oral contrast administration. Administer 1,000–1,500 mL of a biphasic (low-density, T2-hyperintense) oral contrast agent in divided doses over 45–60 minutes prior to scanning to achieve adequate small bowel distention — this single preparatory step has more influence on diagnostic quality than any sequence parameter chosen at the console.
Coil selection and positioning. Use a torso phased-array coil positioned to cover the entire small bowel from the ligament of Treitz to the rectum, including the perianal soft tissues.
Localizer and coverage planning. Acquire a tri-plane localizer confirming adequate distention throughout the visualized small bowel; if distention is inadequate, consider a short delay and re-localize before proceeding.
Intravenous antispasmodic administration. Administer Buscopan 20 mg IV (or glucagon 1 mg IV if Buscopan is contraindicated) immediately prior to breath-held/dynamic sequences to suppress peristalsis-related motion artifact.
Coronal and axial T2 HASTE. Acquire fast single-shot T2 sequences with and without fat saturation to assess mural signal, luminal content, and mesenteric fat stranding.
Coronal/axial FIESTA/TrueFISP. Acquire balanced steady-state free precession imaging for high-contrast, motion-resistant morphological assessment of bowel wall and lumen.
Cine motility sequence. Acquire a repeated coronal SSFP sequence over the mid-small bowel across roughly 20 seconds (before antispasmodic takes full effect, or as a dedicated pre-antispasmodic acquisition) to assess for fixed, non-distensible (fibrotic) segments versus normally peristalsing bowel.
Axial DWI. Acquire diffusion-weighted imaging (b=0, 400, 800 s/mm²) with ADC map generation — restricted diffusion correlates with active inflammatory activity and is particularly useful in patients who cannot receive gadolinium.
Multiphase post-contrast 3D T1 fat-saturated (enteric and delayed phases). Administer the gadolinium bolus and acquire the enteric phase at 45–50 seconds, followed by a delayed phase at 5–7 minutes, to assess mural enhancement pattern and stratification, and to characterize any fistula, sinus tract, or abscess.

Scanner comparison table (1.5T vs. 3.0T)

Parameter	1.5T	3.0T
SSFP (FIESTA/TrueFISP) banding artifact	Uncommon with routine shimming	More frequent due to greater B0 inhomogeneity — requires careful local shimming over the abdomen
SNR	Baseline	~1.7–2× higher, offset by increased susceptibility/banding sensitivity
Fat suppression uniformity across the large FOV	Generally more homogeneous	More prone to peripheral fat-sat failure at the flanks — Dixon-based methods often preferred
SAR headroom for lengthy multi-sequence protocol	Greater — favorable for the many sequences this protocol requires	More restrictive; parallel imaging and flip angle moderation typically required
Achievable enteric-phase temporal resolution	~15–20 s per 3D phase	~10–15 s per 3D phase with acceleration

💉

Precision-Filled Syringes with SATSyringe

Accurately dosed, air-bubble-minimized syringes help hit the 45–50 second enteric-phase window reliably, scan after scan.

Explore SATSyringe →

Contrast Media Protocol

MR enterography relies on precisely timed enteric-phase dynamic contrast imaging to characterize mural enhancement pattern — the single most reliable discriminator between active transmural inflammation and quiescent, fibrotic disease.

Injection Protocol

Volume: 10–15 mL (0.1 mmol/kg) gadolinium-based contrast agent
Flow rate: 3.0 mL/s
Chaser: 100 mL saline at 3.0 mL/s
Acquisition: Enteric phase at 45–50 seconds; delayed phase at 5–7 minutes

The higher flow rate relative to many other abdominal MRI protocols reflects the need for a compact, well-defined bolus that produces genuine early mural hyperenhancement distinguishable from background enhancement — a diffuse, poorly timed bolus blunts the contrast between actively inflamed and normal bowel wall, directly undermining scoring systems such as MaRIA and the Clermont score that depend on quantifiable relative enhancement.

Safety Check Confirm eGFR and screen for Buscopan contraindications (narrow-angle glaucoma, myasthenia gravis, significant tachyarrhythmia, unstable cardiovascular disease, and severe prostatic hypertrophy with urinary retention) before every study. Glucagon is the preferred alternative antispasmodic in these patients, though it carries its own caution in patients with insulinoma or pheochromocytoma.

Specific Absorption Rate & Dose Reduction

MR enterography’s combination of large-FOV balanced SSFP sequences, repeated cine acquisitions, and multiphase fat-saturated dynamic imaging makes it one of the more RF-intensive abdominal protocols, particularly at 3T.

Regulatory Body	Whole-body SAR limit (normal mode)	Relevance to enterography protocol
ICRP	Guidance framework for RF exposure, not device-specific limits	Underpins the general as-low-as-reasonably-achievable (ALARA) principle applied to RF exposure across this multi-sequence protocol
IEC 60601-2-33 / adopted by EC RP 185	2 W/kg whole-body (normal operating mode)	Governs the cumulative RF load of SSFP, cine, and multiphase dynamic sequences performed in a single sitting
AAPM	Practice guidance aligned with IEC limits; emphasizes local monitoring	Recommends departmental SAR auditing for high-duty-cycle, multi-sequence abdominal protocols such as this one

Five dose reduction strategies

Moderate the flip angle on balanced SSFP sequences, particularly at 3T, since SSFP is inherently RF-intensive due to short TR.
Employ parallel imaging on the multiphase dynamic 3D T1 fat-saturated sequences to reduce total RF pulses per phase.
Sequence the protocol thoughtfully — placing the cine motility acquisition before antispasmodic administration avoids a redundant additional acquisition later in the study.
Use hybrid fat suppression techniques (SPAIR or Dixon-based) rather than stacked spectral presaturation pulses across every sequence.
Limit delayed-phase acquisitions to cases where a specific penetrating complication is suspected, rather than acquiring routine additional late phases in every patient.

🧪

Consistent Saline Chaser Dilution with SATMix

Standardized contrast-to-saline mixing supports a compact, well-defined bolus for reliable enteric-phase mural enhancement assessment.

Explore SATMix →

Top 10 Pathologies

Active inflammatory Crohn’s ileitis

T1: hypointense wall, avid layered enhancement · T2: hyperintense wall

Mural hyperenhancement, wall thickening >3 mm, restricted diffusion, and adjacent comb sign.

Fibrostenotic stricture

T1: iso-to-hypointense wall, mild delayed enhancement · T2: relatively hypointense wall

Fixed luminal narrowing on cine motility with pre-stenotic dilatation; minimal restricted diffusion.

Penetrating/fistulizing disease

T1: enhancing tract on post-contrast fat-sat · T2: hyperintense tract if fluid-filled

Enteroenteric, enterocutaneous, or enterovesical fistula tracking between an inflamed segment and an adjacent structure.

Intra-abdominal/pelvic abscess

T1: hypointense, rim-enhancing · T2: markedly hyperintense center, restricted diffusion

Rim-enhancing fluid collection, often adjacent to a penetrating fistula tract — surgical/IR referral trigger.

Perianal fistulizing disease

T1: hypointense tract · T2: hyperintense tract, “candlestick” branching pattern

Requires dedicated coverage of the perianal soft tissues on every enterography study.

Backwash ileitis (ulcerative colitis)

T1: mild wall thickening · T2: mild hyperintensity, patulous ileocecal valve

Mild, non-transmural terminal ileal inflammation contiguous with active pancolitis — distinguishes from Crohn’s skip lesions.

Small bowel lymphoma

T1: homogeneous, moderate enhancement · T2: mild hyperintensity

Circumferential, aneurysmal luminal dilatation without obstruction — a key mimicker of stricturing Crohn’s disease.

Celiac disease

T1: unremarkable wall signal · T2: unremarkable

Jejunal fold pattern reversal (jejunization of ileum) and mesenteric lymph node enlargement rather than focal wall thickening.

NSAID enteropathy (diaphragm disease)

T1: focal thin web · T2: subtle mural signal change

Short-segment concentric webs causing luminal narrowing, typically without the transmural inflammation of Crohn’s disease.

Adhesive small bowel obstruction

T1: dilated fluid-filled loops · T2: markedly hyperintense proximal loops

Transition point without associated mural hyperenhancement — a non-inflammatory mimicker relevant in post-surgical patients.

🔬

Confident Bowel Characterization Starts with SATline

Reliable, consistent contrast delivery lines are what separate a diagnostic enteric-phase acquisition from a technically limited study.

Explore SATline →

Pitfalls — Radiographers

Primary scanning pitfall (from protocol data): Bowel peristalsis motion degrading image quality when the intravenous antispasmodic is omitted, under-dosed, or mistimed relative to the dynamic sequences.

Category	Description	Mitigation
Antispasmodic omission or mistiming	Buscopan/glucagon administered too early loses effect before the enteric-phase dynamic sequence, or is omitted altogether, allowing peristalsis to blur mural detail on the diagnostically critical post-contrast phases.	Administer the antispasmodic immediately before the T2/SSFP and dynamic contrast block, timed so peak effect (roughly 1–10 minutes post-injection for Buscopan) covers the enteric-phase acquisition.
Inadequate oral contrast distention	Insufficient volume or too-short an ingestion window leaves the terminal ileum and jejunum under-distended, mimicking or masking true wall thickening.	Confirm the full 1,000–1,500 mL volume was consumed over the full 45–60 minute window before proceeding; re-localize and delay if distention is visibly inadequate.
Enteric-phase mistiming	Manual time-delay estimation without bolus tracking risks acquiring the dynamic phase before or after the true 45–50 second enteric window.	Use test-bolus timing or automated bolus-triggering software rather than a fixed universal delay.
Incomplete perianal/pelvic coverage	FOV centered tightly on the mid-abdomen misses perianal fistulizing disease relevant to a meaningful proportion of Crohn’s patients.	Extend coverage inferiorly to include the perianal soft tissues by protocol default, regardless of the primary indication.
SSFP banding artifact from poor shimming	Off-resonance banding across the large abdominal FOV, more pronounced at 3T, can mimic or obscure subtle mural findings.	Perform dedicated local shimming centered on the small bowel rather than relying on whole-FOV default shimming.

Pitfalls — Radiologists

Primary interpretation pitfall (from protocol data): Mistaking a collapsed, under-distended, or motion-blurred bowel loop for a pathologically thickened, actively inflamed segment — the direct interpretive consequence of inadequate distention or unmitigated peristalsis artifact at acquisition.

Pitfall	Mechanism	Consequence	Mitigation
Pseudo-thickening from under-distention	A collapsed normal loop of bowel has a genuinely thicker apparent wall than the same loop when properly distended, since wall thickness measurement is distention-dependent.	False-positive diagnosis of active disease, unnecessary escalation of medical therapy.	Only assess wall thickness and enhancement on segments confirmed to be adequately distended on at least one sequence; re-review the cine motility series to confirm the segment was not simply in a peristaltic contraction phase.
Motion-blurred wall stratification misread as normal	Residual peristalsis blur on inadequately antispasmodic-covered phases can smooth over the layered enhancement pattern that distinguishes active inflammation from normal wall.	False-negative interpretation of a technically limited but genuinely active segment.	Explicitly document technical adequacy/motion degradation in the report rather than silently reporting a normal-appearing but degraded segment as definitively normal.
Fibrotic vs. inflammatory stricture misclassification	Relying on wall thickness alone rather than combining cine motility (distensibility), T2 signal, and enhancement pattern to distinguish a fixed fibrotic segment from an actively inflamed one.	Inappropriate escalation of biologic therapy for a purely fibrotic stricture that will not respond, or conversely undertreatment of an actively inflamed segment.	Systematically integrate all three data sources — distensibility on cine, T2 signal, and enhancement pattern/timing — before characterizing a stricture, per current MaRIA/Clermont-informed reporting practice.
Missed skip lesions from incomplete segment-by-segment review	Attention concentrated on the terminal ileum, the most common site, can cause proximal jejunal or duodenal skip lesions to be overlooked.	Underestimation of true disease extent, affecting surgical planning in candidates for segmental resection.	Perform a systematic, segment-by-segment review from duodenum to rectum on every study, not only a focused review of the terminal ileum.

Pitfalls — Non-Radiology Physicians

Pitfall	What they see	What it actually is	Clinical danger	What to do
Accepting a technically limited MRE as a true negative	A report stating “no definite active disease identified” without noting distention or motion limitations	Often a study where a specific segment was inadequately distended or motion-degraded, not a genuine, fully evaluated negative	False reassurance leading to premature de-escalation of therapy	Read the technical adequacy statement in the report, and if absent, ask radiology whether all segments — particularly the terminal ileum — were adequately assessed
Ordering MRE in patients unable to tolerate oral contrast volume	A standing order for “MR enterography” applied uniformly	A patient with severe nausea, short bowel syndrome, or high-grade obstruction who cannot realistically ingest 1–1.5 L of oral contrast	An inadequately distended, non-diagnostic study and a wasted appointment slot	Flag known obstructive symptoms or oral intolerance to radiology in advance so an alternative protocol (e.g., IV-contrast-only or CT enterography) can be considered
Comparing MRE and CTE findings as directly interchangeable	A prior CTE-based disease extent compared directly to a new MRE report	MRE’s superior soft-tissue contrast can detect subtler mural and extramural changes that CTE under-called, or vice versa for calcified/dense findings	Misinterpreting a modality-driven difference as true interval change in disease activity	Request same-modality comparison when possible, and ask radiology to clarify whether an apparent change reflects true progression or modality sensitivity
Treating MaRIA/Clermont score changes as the sole activity marker	A single quantitative activity score reported without full context	These scores are validated adjuncts, not replacements for clinical, endoscopic, and biomarker correlation	Management decisions made on imaging score alone without cross-checking symptoms and biomarkers	Integrate the MRE report with clinical disease activity indices and biomarkers such as fecal calprotectin before adjusting therapy

📋

Reduce Repeat Scans with SATSyringe

Consistent, accurately dosed contrast delivery reduces mistimed enteric phases that lead to technically limited, non-diagnostic reports.

Explore SATSyringe →

Pitfall Comparison Summary

🟡 Scanning (Radiographers)

Antispasmodic omitted or mistimed
Inadequate oral contrast distention
Enteric-phase mistiming
Incomplete perianal coverage
SSFP banding from poor shimming

🔴 Interpretation (Radiologists)

Pseudo-thickening from under-distention
Motion-blurred stratification misread as normal
Fibrotic vs. inflammatory misclassification
Missed proximal skip lesions

🟣 Clinical (Physicians)

Accepting a limited study as a true negative
Ordering MRE without checking oral tolerance
Cross-modality (MRE vs. CTE) misinterpretation
Over-reliance on activity score alone

AI & Automation in Enterography

Automated bowel segmentation and enhancement quantification tools are increasingly used to generate reproducible MaRIA and Clermont-type activity scores directly from the acquired dynamic and diffusion sequences, reducing the interobserver variability inherent in visual scoring. Several CE-marked platforms now flag segments with restricted diffusion or mural hyperenhancement for radiologist review, functioning as a structured second check against exactly the kind of missed-segment and pseudo-thickening pitfalls described above.

These tools remain adjuncts rather than replacements for radiologist judgment, particularly for the genuinely difficult fibrotic-versus-inflammatory stricture distinction, but growing evidence supports their role in improving reporting consistency across a department’s Crohn’s disease surveillance workload.

🧪

Consistent Inputs Make Better Outputs — SATMix

Whatever quantification or scoring software your department uses, standardized contrast mixing keeps the enhancement data feeding it reliable.

Explore SATMix →

Reducing Artefacts with Patients and Parameters

The most critical scanning parameters that impact image quality include:

1. Spatial Resolution

Spatial resolution defines the ability to distinguish small details in an image. Matrix Size: Increasing the matrix size (frequency × phase) increases spatial resolution, but decreases SNR because the voxel (3D pixel) size becomes smaller. Field of View (FOV): Reducing the FOV increases spatial resolution. However, smaller FOV results in smaller voxels and reduces SNR. Slice Thickness: Thinner slices provide higher spatial resolution and reduce partial volume averaging, but significantly decrease SNR.

2. Signal-to-Noise Ratio (SNR)

SNR represents the strength of the diagnostic signal relative to inherent background noise. A high SNR produces crisp, clear images, whereas a low SNR looks grainy. Number of Averages (NEX/NSA): Increasing averages acquires data multiple times, which improves SNR. However, doubling the averages roughly doubles the scan time. Receiver Bandwidth: Decreasing the bandwidth limits the amount of noise recorded, boosting SNR. However, a lower bandwidth increases scan times and chemical shift artifacts. Coil Selection: Using dedicated, localized surface coils rather than whole-body coils captures much stronger signals and heavily improves SNR.

3. Image Contrast

Contrast determines how different tissues are distinguished from one another (e.g., highlighting bone vs. fluid vs. muscle). Repetition Time (TR): TR is the time between consecutive RF pulses. A short TR maximizes T1 tissue contrast, while a long TR minimizes it. Echo Time (TE): TE is the time between the RF pulse and the peak of the echo signal. A short TE minimizes T2 effects, and a long TE maximizes T2 weighting, making fluid-filled areas appear very bright. Flip Angle: Controls the excitation of protons. Adjusting the flip angle changes tissue contrast and is especially critical in gradient echo sequences.

4. Artifact Control

Artifacts are visual distortions or ghosting that degrade image quality. Phase Encoding Direction: Swapping the phase and frequency axes can shift motion-induced artifacts (like breathing or blood flow) away from the primary region of interest. Flow Compensation / Gating: Utilizes physiological triggers (e.g., electrocardiogram) to minimize blurring and ghosting caused by pulsatile motion. Parallel Imaging: Utilizes multiple coil elements simultaneously to reduce phase encoding steps, significantly cutting down scan time and reducing motion artifacts.

Parallel Imaging Protocols and Parameters

Parallel imaging acceleration is central to keeping this multi-sequence protocol within the antispasmodic’s effective window and within patient tolerance for a large-volume oral contrast preparation. Turbo/echo-train factor and acceleration factor selection interact directly with achievable spatial resolution and motion sensitivity.

Sequence	Parameter	1.5T typical setting	3.0T typical setting	Adjustment for optimal quality
T2 HASTE	Turbo factor (echo train length)	128–160	128–160	Reduce TE and increase parallel imaging factor at 3T to offset higher effective RF duty cycle in this lengthy protocol
FIESTA/TrueFISP (SSFP)	Flip angle / bandwidth	Moderate flip angle, standard bandwidth	Reduced flip angle, higher bandwidth to limit banding	At 3T, prioritize local shimming and higher receiver bandwidth over flip angle increases to control banding artifact
Cine motility (repeated SSFP)	Temporal resolution	~1 frame/s over ~20 s	~1–1.5 frames/s over ~20 s	Keep turbo factor low enough to preserve true temporal fidelity of peristaltic motion — over-acceleration here defeats the sequence’s purpose
Dynamic 3D T1 FS	Acceleration (SENSE/GRAPPA) factor	2×	2–3× (SAR headroom permitting)	Increase acceleration at 3T primarily to hit the narrow 45–50 second enteric window, paired with modest flip angle reduction

As a general principle: increasing turbo factor shortens acquisition and reduces residual peristalsis sensitivity but blurs fine mucosal and mural detail — a meaningful concern for detecting subtle early mural stratification. The optimal balance for enterography protocols favors moderate turbo factors on T2 HASTE, careful flip angle and bandwidth management on SSFP sequences to control banding, and higher parallel imaging acceleration specifically on the time-critical enteric-phase dynamic acquisition.

Conclusion

A technically sound MR enterography protocol rests on four pillars: adequate oral luminal distention achieved through disciplined patient preparation; reliable pharmacological suppression of peristalsis timed to cover the diagnostically critical dynamic sequences; a coordinated sequence set — T2 HASTE, FIESTA/TrueFISP, cine motility, DWI, and multiphase enteric-timed dynamic contrast — that together answers the three central clinical questions of activity, fibrosis, and penetrating complication; and disciplined awareness of the distinct pitfall patterns that affect radiographers at acquisition, radiologists at interpretation, and referring physicians acting on the final report.

From active inflammatory ileitis through fibrostenotic stricture, penetrating fistulizing disease, and the several important mimickers small bowel imaging must exclude, the protocol’s diagnostic power depends on treating patient preparation as inseparable from technical execution. Departments that standardize oral contrast timing, antispasmodic administration, and enteric-phase bolus timing consistently produce more diagnostic, less ambiguous MR enterography reports — supporting the lifelong surveillance imaging that Crohn’s disease management increasingly requires.

References

American College of Radiology. (2023). ACR manual on contrast media (Version 2023). American College of Radiology. acr.org/Clinical-Resources/Contrast-Manual
Rimola, J., Rodriguez, S., Garcia-Bosch, O., Ordas, I., Ayala, E., Aceituno, M., Pellise, M., Ayuso, C., Ricart, E., Donoso, L., & Panes, J. (2015). Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Journal of Crohn’s and Colitis, 9(5), 449–457. https://doi.org/10.1093/ecco-jcc/jjv035
Rimola, J., Alvarez-Cofiño, A., Pérez-Jeldres, T., Ayuso, C., Alfaro, I., Rodríguez, S., Ricart, E., & Panés, J. (2017). Comparison of three magnetic resonance enterography indices for grading activity in Crohn’s disease. Journal of Gastroenterology, 52(5), 585–593. https://doi.org/10.1007/s00535-016-1246-5
Moy, M. P., Sauk, J., & Gee, M. S. (2016). The role of MR enterography in assessing Crohn’s disease activity and treatment response. Gastroenterology Research and Practice, 2016, 8168695. https://doi.org/10.1155/2016/8168695
Taylor, S. A., Avni, F., Cronin, C. G., Hoeffel, C., Kim, S. H., Laghi, A., Napolitano, M., Petit, P., Rimola, J., Stoker, J., Zappa, M., Bhatnagar, G., Puylaert, C. A. J., Stijns, R., Tielbeek, J. A. W., & Panes, J. (2017). The first joint ESGAR/ESPR consensus statement on the technical performance of cross-sectional small bowel and colonic imaging. European Radiology, 27(6), 2570–2582. https://doi.org/10.1007/s00330-016-4615-9
Bruining, D. H., Zimmermann, E. M., Loftus, E. V., Sandborn, W. J., Sauer, C. G., Strong, S. A., & Society of Abdominal Radiology Crohn’s Disease-Focused Panel. (2018). Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn’s disease. Radiology, 286(3), 776–799. https://doi.org/10.1148/radiol.2018171737
Fiorino, G., Bonifacio, C., Peyrin-Biroulet, L., Minuti, F., Repici, A., Spinelli, A., Fries, W., Balzarini, L., Montorsi, M., Malesci, A., & Danese, S. (2011). Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflammatory Bowel Diseases, 17(5), 1073–1080. https://doi.org/10.1002/ibd.21533
Deepak, P., & Bruining, D. H. (2015). Radiographical evaluation of ulcerative colitis. Gastroenterology Report, 3(3), 173–182. https://doi.org/10.1093/gastro/gov027
Jesuratnam-Nielsen, K., Løgager, V. B., Rezanavaz-Gheshlagh, B., Munkholm, P., & Thomsen, H. S. (2015). Plain magnetic resonance imaging as an alternative in evaluating inflammation and bowel damage in inflammatory bowel disease — a prospective comparison with conventional magnetic resonance follow-through. Scandinavian Journal of Gastroenterology, 50(3), 519–527. https://doi.org/10.3109/00365521.2014.994642
Guglielmo, F. F., Anupindi, S. A., Fletcher, J. G., Al-Hawary, M. M., Dillman, J. R., Grand, D. J., Bruining, D. H., Chatterji, M., Darge, K., Fidler, J. L., Gandhi, N. S., Gee, M. S., Grajo, J. R., Huang, C., Jaffe, T. A., Park, S. H., Rimola, J., Sokol, S. K., Strong, S. A., … Baker, M. E. (2020). Small bowel Crohn disease at CT and MR enterography: Imaging atlas and glossary of terms. RadioGraphics, 40(2), 354–375. https://doi.org/10.1148/rg.2020190091
Jannatdoust, P., Valizadeh, P., Razaghi, M., Rouzbahani, M., Abbasi, A., & Arian, A. (2023). Role of abbreviated non-contrast-enhanced MR-enterography in the evaluation of Crohn’s disease activity and complications as an alternative for full protocol contrast-enhanced study: A systematic review and meta-analysis. Radiography Extra/Redii, 9, 100030. https://doi.org/10.1016/j.redii.2023.100030
Cronin, C. G., Lohan, D. G., Mhuircheartaigh, J. N., Meehan, C. P., Murphy, J., Roche, C., & Cody, D. (2010). MRI small-bowel follow-through: Prone versus supine patient positioning for best small-bowel distention and lesion detection. American Journal of Roentgenology, 194(2), 502–506. https://doi.org/10.2214/AJR.09.2338
Amitai, M. M., Ben-Horin, S., Eliakim, R., & Kopylov, U. (2013). Magnetic resonance enterography in Crohn’s disease: A guide to common imaging manifestations for the IBD physician. Journal of Crohn’s and Colitis, 7(8), 603–615. https://doi.org/10.1016/j.crohns.2012.10.005
Kilcoyne, A., Kaplan, J. L., & Gee, M. S. (2016). Inflammatory bowel disease imaging: Current practice and future directions. World Journal of Gastroenterology, 22(3), 917–932. https://doi.org/10.3748/wjg.v22.i3.917
Steward, M. J., Punwani, S., Proctor, I., Adjei-Gyamfi, Y., Chatterjee, F., Bloom, S., Novelli, M., Halligan, S., & Taylor, S. A. (2012). Non-perforating small bowel Crohn’s disease assessed by MRI enterography: Derivation and histopathological validation of an MR-based activity index. European Journal of Radiology, 81(9), 2080–2088. https://doi.org/10.1016/j.ejrad.2011.07.013
Ordás, I., Rimola, J., Rodríguez, S., Paredes, J. M., Martínez-Pérez, M. J., Blanc, E., Arévalo, J. A., Aduna, M., Andreu, M., Radosevic, A., Ramírez-Morros, A. M., Pinó-Donnay, S., Castro, M., Vilalta, A. M., Martín, C., Fernández-Clotet, A., Ricart, E., Ayuso, C., & Panés, J. (2014). Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology, 146(2), 374–382.e1. https://doi.org/10.1053/j.gastro.2013.10.055
Lu, C., Merrill, C., Medellin, A., Novak, K., & Wilson, S. R. (2017). Bowel ultrasound state of the art: Grayscale and Doppler ultrasound, contrast enhancement, and elastography in Crohn disease. Journal of Ultrasound in Medicine, 36(1), 47–63. https://doi.org/10.7863/ultra.16.02010
Church, P. C., Turner, D., Feldman, B. M., Greer, M. L. C., Wils, P., Griffiths, A. M., & PROTECT Study Group. (2018). Systematic review with meta-analysis: Magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn’s disease. Alimentary Pharmacology & Therapeutics, 41(2), 153–166. https://doi.org/10.1111/apt.13024
Rimola, J., Ordás, I., Rodriguez, S., García-Bosch, O., Aceituno, M., Llach, J., Ayuso, C., Ricart, E., & Panés, J. (2011). Magnetic resonance imaging for evaluation of Crohn’s disease: Validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases, 17(8), 1759–1768. https://doi.org/10.1002/ibd.21551
Grand, D. J., Kampalath, V., Harris, A., Patel, A., Resnick, M. B., Machan, J. T., & Beland, M. D. (2012). MR enterography correlates highly with colonoscopy and histology for both distal ileal and colonic Crohn’s disease in 310 patients. European Journal of Radiology, 81(11), e763–e769. https://doi.org/10.1016/j.ejrad.2012.02.014
Levin, A., & Stevens, P. E. (2024). Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4), 684–701. https://doi.org/10.1016/j.kint.2023.10.016
European Society of Urogenital Radiology. (2018). ESUR guidelines on contrast agents (Version 10.0). ESUR. esur.org/esur-guidelines-on-contrast-agents
Bhatnagar, G., Von Stempel, C., Halligan, S., & Taylor, S. A. (2017). Utility of MR enterography and ultrasound for the investigation of small bowel Crohn’s disease. Journal of Magnetic Resonance Imaging, 45(4), 1573–1583. https://doi.org/10.1002/jmri.25569
Sinha, R., Rajiah, P., Ramachandran, I., Sanders, S., & Murphy, P. D. (2012). Diffusion-weighted MR imaging of the gastrointestinal tract: Technique, indications, and imaging findings. RadioGraphics, 32(2), 391–409. https://doi.org/10.1148/rg.322115063
Fidler, J. L., Guimaraes, L., & Einstein, D. M. (2009). MR imaging of the small bowel. RadioGraphics, 29(6), 1811–1825. https://doi.org/10.1148/rg.296095507
International Commission on Radiological Protection. (2020). ICRP publication 147: Use of dosimetric quantities for regulatory purposes. ICRP. icrp.org/publication.asp?id=ICRP Publication 147
SATMED Health. (2026, May 31). 7 proven strategies for optimizing MRI sequences in 2026. https://www.satmed-health.com/optimizing-mri-sequences/
SATMED Health. (2026, March 1). 2026 contrast media guidelines: eGFR thresholds & safe administration protocol. https://www.satmed-health.com/2026-worldwide-guidelines…
Lee, S. S., Kim, A. Y., Yang, S.-K., Chung, J. W., Kim, S. Y., Park, S. H., & Ha, H. K. (2009). Crohn disease of the small bowel: Comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology, 251(3), 751–761. https://doi.org/10.1148/radiol.2513081184
Bruining, D. H., Loftus, E. V., Ehman, E. C., Siddiki, H. A., Nguyen, D. L., Fidler, J. L., Huprich, J. E., Mandrekar, J., Harmsen, W. S., Sandborn, W. J., & Fletcher, J. G. (2011). Magnetic resonance enterography detects small bowel inflammation in symptomatic patients with normal endoscopic findings. Inflammatory Bowel Diseases, 17(5), 1174–1181. https://doi.org/10.1002/ibd.21446

Medically Reviewed by Prof. Dr. Damien O’Neil, MD, PhD

Last updated: July 8, 2026 | Reviewed for clinical accuracy and adherence to the latest guidelines of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), American College of Radiology (ACR), Radiological Society of North America (RSNA), European Crohn’s and Colitis Organisation (ECCO), and the International Commission on Radiological Protection (ICRP).

(Organisations adjusted to those relevant to gastrointestinal/small bowel protocols.)

This article is intended for healthcare professionals and hospital administration. It does not constitute individual clinical advice. Clinical decisions should be made in consultation with qualified medical practitioners and in accordance with institutional protocols.

MR Enterography Protocol: 10 Steps to Master Scans